Using this strategy, we found that topoisomerase and cyclin-dependent kinase (CDK) inhibitors potentially reverse ReCa signatures and inhibit the growth of colorectal cancer (CRC) cell lines closely representing ReCa signatures. The gene discussed is RAD51; the disease is colorectal carcinoma.